Clinical Trials Logo

Bullous Pemphigoid clinical trials

View clinical trials related to Bullous Pemphigoid.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04612790 Terminated - Bullous Pemphigoid Clinical Trials

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

FJORD
Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).

NCT ID: NCT03286582 Terminated - Bullous Pemphigoid Clinical Trials

A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

Start date: September 5, 2017
Phase: Phase 2
Study type: Interventional

Bullous pemphigoid (BP) is a chronic, inflammatory, subepidermal, autoimmune blistering disease which mainly develops in the elderly, with onset usually in the late 70s and a substantial increase in incidence in people older than 80 years. If untreated, it can persist for months or years, with periods of spontaneous remissions and exacerbations. It has been found that blisters and sera of BP patients contain abnormally high levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and IL-8. Recently, it also has been demonstrated that NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome components (the NLRP3-caspase-1-IL-18 axis) were significantly up-regulated in peripheral blood mononuclear cells from BP patients and positively correlated with disease activity. AC-203 is a topical formulation of an oral modulator of inflammasome and IL-1beta pathways. In vitro studies have demonstrated that AC-203 significantly reduced secretion of IL-6 and moderately reduced IL-8 secretion in HaCaT cells treated with specific anti-BP180 IgG. This study is designed to test the safety, tolerability, efficacy, and pharmacokinetics of AC-203 ointment (vs. a topical steroid comparator representing standard of care) ointment in subjects with BP.

NCT ID: NCT01688882 Terminated - Bullous Pemphigoid Clinical Trials

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Start date: January 2013
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity. How QGE031 is broken down by the body and the impact it has on different blood and tissue markers will also be explored.

NCT ID: NCT01571895 Terminated - Bullous Pemphigoid Clinical Trials

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

Start date: February 20, 2012
Phase: Phase 2
Study type: Interventional

The objective of this clinical trial was to evaluate whether DF2156A has a potential in improving the clinical outcome in patients with active blistering bullous pemphigoid (BP) to warrant its further development. The safety of DF2156A in the specific clinical setting was also evaluated.